Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptidyl arginine deiminase 2 (PADI2) is an enzyme that catalyzes the conversion of protein-bound arginine residues into citrulline. It requires calcium ions for enzymatic activity and is involved in myelination, immune regulation, and gene expression. PADI2 is implicated in diseases like multiple sclerosis, rheumatoid arthritis, and cancer, making it a potential drug target.
Inhibition of PADI2 enzymatic activity, preventing citrullination of target proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Peptidyl Arginine Deiminase 2 (PADI2).